Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Net Margin (2023 - 2025)

CG Oncology (CGON) has disclosed Net Margin for 3 consecutive years, with 1776.74% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 519650.0% year-over-year to 1776.74%, compared with a TTM value of 3981.26% through Dec 2025, up 374824.0%, and an annual FY2025 reading of 3985.02%, up 374447.0% over the prior year.
  • Net Margin was 1776.74% for Q4 2025 at CG Oncology, up from 2623.53% in the prior quarter.
  • Across five years, Net Margin topped out at 1776.74% in Q4 2025 and bottomed at 2249000.0% in Q4 2023.
  • Average Net Margin over 3 years is 259535.86%, with a median of 12001.94% recorded in 2024.
  • The sharpest move saw Net Margin soared 224202675bps in 2024, then plummeted -6306271bps in 2025.
  • Year by year, Net Margin stood at 2249000.0% in 2023, then skyrocketed by 100bps to 6973.25% in 2024, then soared by 75bps to 1776.74% in 2025.
  • Business Quant data shows Net Margin for CGON at 1776.74% in Q4 2025, 2623.53% in Q3 2025, and 66263.46% in Q1 2025.